載入...
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab co...
Na minha lista:
| 發表在: | Mult Scler |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5971363/ https://ncbi.nlm.nih.gov/pubmed/28485678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517708464 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|